Article
Cabozantinib Is Active against Human Gastrointestinal Stromal Tumor Xenografts Carrying Different KIT Mutations.
Molecular cancer therapeutics - 1 Dec 2016
Gebreyohannes Yemarshet K, Schöffski Patrick, Van Looy Thomas, Wellens Jasmien, Vreys Lise, Cornillie Jasmien, Vanleeuw Ulla, Aftab Dana T, Debiec-Rychter Maria, Sciot Raf, Wozniak Agnieszka
Abstract excerpt
In the majority of gastrointestinal stromal tumors (GIST), oncogenic signaling is driven by KIT mutations. Advanced GIST is treated with tyrosine kinase inhibitors (TKI) such as imatinib. Acquired resistance to TKI is mainly caused by secondary KIT mutations, but can also be attributed to a switch of KIT dependency to another receptor tyrosine kinase (RTK). We tested the efficacy of cabozantinib, a novel TKI...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.